How Much Does Low-Dose Naltrexone Cost in North Dakota in 2026?

What Low-Dose Naltrexone Actually Costs in North Dakota

The average cash-pay price for LDN across North Dakota retail and compounding pharmacies in 2026 is $50 per month. This price applies to compounded oral capsules dispensed by 503A pharmacies, which represent the primary supply channel for LDN in the state.

That $50 figure holds remarkably steady across North Dakota. Unlike branded pharmaceuticals where pricing swings wildly between Fargo, Bismarck, Grand Forks, and rural communities, compounded LDN pricing stays consistent because 503A pharmacies set their own rates based on raw naltrexone powder costs rather than manufacturer list prices. The active ingredient itself is inexpensive. Naltrexone hydrochloride is a decades-old generic compound first approved by the FDA in 1984 for opioid dependence 1. Most of the $50 monthly cost covers compounding labor, capsule fills, quality testing, and dispensing fees.

For context, a 30-day supply of standard-dose naltrexone (50 mg tablets) runs $25 to $65 at North Dakota chain pharmacies with a GoodRx-type discount coupon. LDN requires compounding because no manufacturer produces naltrexone in the 1.5 mg to 4.5 mg dose range used for off-label anti-inflammatory purposes. This compounding step is what makes LDN slightly more expensive per milligram than its full-dose counterpart.

Patients paying out of pocket should expect to budget $600 annually for LDN alone, not including prescriber visit fees or any required lab work. Some telehealth platforms bundle the consultation and prescription into a single monthly fee ranging from $75 to $125, which includes the cost of the compounded medication shipped directly to the patient's door 2.

Why LDN Requires Compounding and What 503A Means

LDN is not an FDA-approved product at its low-dose range. The FDA approved naltrexone at 50 mg for opioid and alcohol use disorders, but the 1.5 mg to 4.5 mg doses prescribed off-label must be prepared by a compounding pharmacy.

In North Dakota, 503A compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. These pharmacies compound medications based on individual patient prescriptions from a licensed prescriber. They do not manufacture drugs in bulk for general distribution. North Dakota's Board of Pharmacy licenses and inspects these facilities, and compounded LDN from a 503A pharmacy in the state is legal when dispensed pursuant to a valid prescription 3.

The distinction matters for cost. A 503B outsourcing facility can produce larger batches and may offer lower per-unit pricing, but most North Dakota patients access LDN through 503A pharmacies, either locally or via mail-order from out-of-state compounders licensed to ship into North Dakota. Both routes yield the same approximate $50 per month price point.

Patients should verify that any compounding pharmacy they use holds current licensure with the North Dakota Board of Pharmacy. The Board maintains a public database of licensed pharmacies. Using an unlicensed compounder exposes patients to quality risks, as compounded drugs do not undergo the same FDA review process as commercially manufactured products 4.

North Dakota Medicaid and LDN Coverage

North Dakota Medicaid does not cover low-dose naltrexone for off-label indications such as fibromyalgia, chronic pain, or autoimmune conditions. This is consistent with most state Medicaid programs nationwide.

The coverage gap exists because LDN lacks FDA approval at the low-dose range. Medicaid formularies generally require FDA approval or a compendia listing for a specific indication before covering a medication. Since no pharmaceutical manufacturer has pursued FDA approval for naltrexone at 1.5 mg to 4.5 mg, there is no approved labeling for Medicaid to reference. The North Dakota Department of Health and Human Services administers the state's Medicaid program, and its preferred drug list does not include compounded LDN 5.

Standard-dose naltrexone (50 mg) may be covered under North Dakota Medicaid for its approved indications of opioid use disorder and alcohol use disorder. Patients with both an approved-indication diagnosis and an off-label need should discuss coverage options with their prescriber, though prior authorization for the full-dose tablet will not translate into coverage for a compounded low-dose formulation.

For North Dakota Medicaid beneficiaries who want to try LDN, the $50 monthly out-of-pocket cost remains the primary pathway. Some patients have successfully appealed Medicaid denials in other states by submitting peer-reviewed literature and physician letters of medical necessity, but North Dakota has no published precedent for approving such appeals for compounded LDN.

Private Insurance Coverage for LDN in North Dakota

Most private insurers in North Dakota, including Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica, do not routinely cover compounded LDN. The reasons mirror Medicaid's position: no FDA approval at the low-dose range and no standard billing code specific to compounded naltrexone.

Some patients have obtained partial reimbursement by submitting out-of-network pharmacy claims with supporting documentation. Success rates are low. A 2020 survey published in the Journal of Managed Care & Specialty Pharmacy found that fewer than 8% of compounded medication claims submitted to commercial insurers were reimbursed at any level 6.

Patients with health savings accounts (HSAs) or flexible spending accounts (FSAs) can typically use these tax-advantaged funds to pay for compounded LDN, as it is a prescribed medication. This effectively reduces the real cost by the patient's marginal tax rate. For a North Dakota resident in the 22% federal bracket, that $50 monthly cost drops to about $39 in after-tax dollars when paid through an HSA.

Employer-sponsored plans with pharmacy benefit managers (PBMs) like Express Scripts or CVS Caremark occasionally cover compounded medications if the prescriber obtains prior authorization and documents medical necessity. The effort required often exceeds the cost savings for a $50-per-month medication, but patients with complex autoimmune conditions who take multiple compounded drugs may find the prior authorization process worthwhile for their overall pharmacy spend.

Telehealth Access to LDN in North Dakota

Telehealth prescribing of low-dose naltrexone is legal in North Dakota. The state's telehealth laws, updated during and after the COVID-19 public health emergency, permit licensed prescribers to evaluate patients and write prescriptions via audio-video consultation without requiring an in-person visit first 7.

Several national telehealth platforms now serve North Dakota patients seeking LDN prescriptions. These platforms typically employ or contract with physicians or nurse practitioners licensed in North Dakota who can evaluate, prescribe, and coordinate with a compounding pharmacy. The consultation-plus-medication bundle usually costs $75 to $125 per month all-in.

For rural North Dakota residents, and that describes a large portion of the state's population, telehealth eliminates a significant access barrier. The nearest compounding pharmacy may be hours away. Telehealth prescribers can send prescriptions electronically to mail-order compounding pharmacies that ship directly to patients anywhere in the state.

A prescriber must hold an active North Dakota medical license or be authorized through an interstate compact to prescribe in the state. The North Dakota Board of Medicine participates in the Interstate Medical Licensure Compact, which simplifies multi-state licensing for physicians 8. Patients should confirm their telehealth provider's North Dakota licensure before their appointment.

The Clinical Evidence Behind LDN

LDN's off-label use is supported by a growing but still limited body of clinical evidence. The foundational pilot study by Younger et al. (2009) enrolled 10 women with fibromyalgia and found that LDN at 4.5 mg per day reduced fibromyalgia symptoms by 30% compared to placebo, as measured by daily self-reported symptom severity scores 2.

A follow-up double-blind, placebo-controlled, crossover trial by the same group (2013, N=31) confirmed these findings, reporting a 28.8% reduction in pain scores with LDN versus 18.0% with placebo (P = 0.016) 9. Dr. Jarred Younger, who led both trials at Stanford University, stated: "Low-dose naltrexone may operate through a novel anti-inflammatory mechanism on microglial cells, which distinguishes it from existing fibromyalgia treatments."

The proposed mechanism involves transient opioid receptor blockade at low doses, which is thought to upregulate endogenous opioid production (the "rebound effect") and suppress microglial activation in the central nervous system. A 2014 review in Clinical Rheumatology summarized the mechanistic and clinical data, noting that LDN "appears to have a specific immunomodulatory effect that differentiates it from simple analgesic therapy" 5.

Beyond fibromyalgia, small trials and case series have explored LDN in Crohn's disease, multiple sclerosis, and complex regional pain syndrome. A 2011 pilot study (N=17) in Crohn's disease reported an 89% response rate and 67% remission rate with LDN 4.5 mg over 12 weeks 10. These results are promising but come from small, single-center studies. No Phase III trial of LDN has been completed for any indication as of May 2026.

The Endocrine Society and the American College of Rheumatology have not issued formal guidelines on LDN use 11. Prescribers who recommend LDN are practicing evidence-informed medicine based on preliminary data, and patients should understand this distinction.

How to Get the Lowest Price for LDN in North Dakota

The $50 monthly baseline is already among the more affordable specialty-adjacent medications, but several strategies can reduce costs further.

Compare compounding pharmacies. Prices vary by $10 to $20 between compounders. Request quotes from at least two 503A pharmacies, including one local and one mail-order option. Some mail-order compounders offer first-month discounts or subscription pricing as low as $35 per month.

Ask about 90-day supplies. Many compounding pharmacies discount multi-month orders. A 90-day supply might run $120 to $135 instead of $150, saving $15 to $30 per quarter.

Use HSA or FSA funds. As noted above, paying with pre-tax health dollars cuts the effective cost by your marginal tax rate.

Check for patient assistance programs. No manufacturer assistance program exists for compounded LDN because there is no brand manufacturer. However, some compounding pharmacy networks offer loyalty or savings cards that reduce the per-fill cost by $5 to $10. These programs function similarly to manufacturer copay cards but are funded by the pharmacy itself as a customer retention tool.

Bundle through telehealth. Some telehealth platforms negotiate volume pricing with partner compounding pharmacies and pass savings to patients. The all-in price may be lower than paying separately for a prescriber visit and pharmacy fill.

North Dakota does not impose a state sales tax, which is a minor but real advantage. In states with pharmacy sales tax, patients pay an additional 4% to 8% on compounded medications.

Starting LDN: What North Dakota Patients Should Expect

Most prescribers initiate LDN at 1.5 mg taken once nightly at bedtime. The dose is increased by 0.5 mg to 1.5 mg every one to two weeks, titrating toward a target of 4.5 mg per night. This slow titration minimizes the most common side effects: vivid dreams, mild headache, and transient nausea, which typically resolve within the first two weeks of therapy 9.

Patients should avoid taking LDN concurrently with opioid medications. Because naltrexone is an opioid receptor antagonist, combining it with opioids can precipitate acute withdrawal. Prescribers typically require patients to be opioid-free for 7 to 14 days before starting LDN 1.

Lab work before starting LDN is minimal. Most prescribers order a basic metabolic panel and liver function tests, as naltrexone carries an FDA boxed warning for hepatotoxicity at the full 50 mg dose. At 4.5 mg, the risk is considered very low, but baseline liver enzymes provide a safety reference 12.

Therapeutic response, if it occurs, typically becomes apparent within 8 to 12 weeks of reaching the target dose. Patients who see no benefit after 12 weeks at 4.5 mg are unlikely to respond, and continuing therapy is not recommended.